Literature DB >> 30401469

Parkinson disease: A systemic review of pain sensitivities and its association with clinical pain and response to dopaminergic stimulation.

Simon Sung1, Nirosen Vijiaratnam2, Daniela Wan Chi Chan3, Michael Farrell4, Andrew H Evans5.   

Abstract

Patients with Parkinson disease (PD) experience hyperalgesia on evoked pain sensitivity testing, although the relationship of this with persistent pain in PD is less certain. Studies examining this have generated contradictory findings. Further, the role of dopaminergic deficiency as an underlying substrate for hyperalgesia is controversial. We report the results of meta-analyses of the PD pain sensitivity literature in an attempt to answer these questions. We identified 429 records, of which ten articles compared pain sensitivity between PD patients that experienced clinical pain (PDP) to those who did not (PDNP), and twenty studies that examined the effect of dopaminergic medications on pain sensitivity in PD patients. PDP patients experienced a moderate increase in pain sensitivity, had more severe disease, required higher dosages of medication, and were more likely to be female when compared to those PDNP patients. PD patients also had reduced pain sensitivity when tested on dopaminergic medications compared to when they were not on medications. Overall, the results of this systematic review and meta-analysis supports the hypothesis that hyperalgesia contributes to clinical pain in PD, and that the underlying mechanism may be dopaminergically driven.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30401469     DOI: 10.1016/j.jns.2018.10.013

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  4 in total

1.  Remifentanil requirement for i-gel insertion is reduced in male patients with Parkinson's disease undergoing deep brain stimulator implantation: an up-and-down sequential allocation trial.

Authors:  Wenjun Meng; Fang Kang; Meirong Dong; Song Wang; Mingming Han; Xiang Huang; Sheng Wang; Juan Li; Chengwei Yang
Journal:  BMC Anesthesiol       Date:  2022-06-24       Impact factor: 2.376

Review 2.  Towards optimising experimental quantification of persistent pain in Parkinson's disease using psychophysical testing.

Authors:  Rory V Smith; Patrick Wilkins; Kirsty Bannister; Tatum M Cummins
Journal:  NPJ Parkinsons Dis       Date:  2021-03-17

3.  A Meta-Analysis of the Effect of Subthalamic Nucleus-Deep Brain Stimulation in Parkinson's Disease-Related Pain.

Authors:  Yu Diao; Yutong Bai; Tianqi Hu; Zixiao Yin; Huangguang Liu; Fangang Meng; Anchao Yang; Jianguo Zhang
Journal:  Front Hum Neurosci       Date:  2021-07-01       Impact factor: 3.169

4.  Opicapone versus placebo in the treatment of Parkinson's disease patients with end-of-dose motor fluctuation-associated pain: rationale and design of the randomised, double-blind OCEAN (OpiCapone Effect on motor fluctuations and pAiN) trial.

Authors:  K Ray Chaudhuri; Per Odin; Joaquim J Ferreira; Angelo Antonini; Olivier Rascol; Mónica M Kurtis; Alexander Storch; Kirsty Bannister; Patrício Soares-da-Silva; Raquel Costa; Diogo Magalhães; José Francisco Rocha
Journal:  BMC Neurol       Date:  2022-03-12       Impact factor: 2.474

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.